Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 34-46

  Bajis, Sahar ^a   Dore, Gregory J ^a   Hajarizadeh, Behzad ^a   Cunningham, Evan B ^a   Maher, Lisa ^a   Grebely, Jason ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Drug use; HCV; Interventions; Linkage to care; Testing; Treatment

Indexed keywords

INTERFERON;

ARTICLE; CASE MANAGEMENT; CONSENSUS; COUNSELING; DRIED BLOOD SPOT TESTING; DRUG USE; EDUCATION; HEPATITIS C; HUMAN; LIVER DISEASE; LOW INCOME COUNTRY; MEDICAL SPECIALIST; MENTAL HEALTH SERVICE; MIDDLE INCOME COUNTRY; PATIENT; PATIENT ASSESSMENT; PATIENT CARE; PATIENT REFERRAL; PATIENT SCHEDULING; PEOPLE WHO INJECT DRUG; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; HEALTH CARE DELIVERY; PSYCHOLOGY; SUBSTANCE ABUSE;

HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85026877525     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.07.002     Document Type: Article

References (84)

1. Aitken, C.K., Kerger, M., Crofts, N., Peer-delivered hepatitis C testing and counselling: A means of improving the health of injecting drug users. Drug and Alcohol Review 21:1 (2002), 33–37.
2. Alavi, M., Grebely, J., Micallef, M., Dunlop, A.J., Balcomb, A.C., Day, C.A., et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clinical Infectious Diseases 57:Suppl. 2 (2013), S62–S69.
3. Alavi, M., Raffa, J.D., Deans, G.D., Lai, C., Krajden, M., Dore, G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 34:8 (2014), 1198–1206.
4. Arain, A., De Sousa, J., Corten, K., Verrando, R., Thijs, H., Mathei, C., et al. Pilot Study: Combining formal and peer education with fibroScan to increase HCV screening and treatment in persons who use drugs. Journal of Substance Abuse Treatment 67 (2016), 44–49.
5. Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D., et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. New England Journal of Medicine 364:23 (2011), 2199–2207.
6. Barocas, J.A., Linas, B.P., Kim, A.Y., Fangman, J., Westergaard, R.P., Acceptability of rapid point-of-care hepatitis C tests among people who inject drugs and utilize syringe-exchange programs. Open Forum Infectious Diseases, 3(2), 2016 (ofw075-ofw075).
7. Beckwith, C.G., Kurth, A.E., Bazerman, L.B., Patry, E.J., Cates, A., Liem, T., et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. Journal of Public Health 38:1 (2016), 130–137.
8. Bottero, J., Boyd, A., Gozlan, J., Carrat, F., Nau, J., Pauti, M.-D., et al. Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: Results of a randomized control trial in persons without healthcare coverage. Open Forum Infectious Diseases, 2(4), 2015 (ofv162-ofv162).
9. Brewer, D.D., Hagan, H., Evaluation of a patient referral contact tracing programme for hepatitis B and C virus infection in drug injectors. Eurosurveillance, 14(14), 2009.
10. Bruggmann, P., Berg, T., Ovrehus, A.L., Moreno, C., Brandao Mello, C.E., Roudot-Thoraval, F., et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis 21:Suppl. 1 (2014), 5–33.
11. Bruggmann, P., Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers. Journal of Viral Hepatitis 19:12 (2012), 829–835.
12. Coats, J.T., Dillon, J.F., The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature. International Journal of Drug Policy 26:11 (2015), 1050–1055.
13. Conway, B., Vafadary, S., Sharma, S., Zahedieh, F., Shravah, J., Raycraft, T., et al. The community pop-up clinic as a tool of engagement for vulnerable populations with HCV and HIV infections. Journal of Hepatitis 2:1 (2015), 1–4.
14. Cosmaro, M.L., Oldrini, M., Rancilio, L., Villa, A.M., Parisi, M.R., Lazzarin, A., et al. Facilitated access procedures for HIV and HCV testing in vulnerable groups. Infection, 39, 2011, S33.
15. Cousien, A., Tran, V.C., Deuffic-Burban, S., Jauffret-Roustide, M., Dhersin, J.S., Yazdanpanah, Y., Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology 63:4 (2016), 1090–1101.
16. Craine, N., Parry, J., O'Toole, J., D'Arcy, S., Lyons, M., Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. Journal of Viral Hepatitis 16:3 (2009), 219–222.
17. Cullen, W., Stanley, J., Langton, D., Kelly, Y., Staines, A., Bury, G., Hepatitis C infection among injecting drug users in general practice: A cluster randomised controlled trial of clinical guidelines’ implementation. British Journal of General Practice 56:532 (2006), 848–856.
18. Day, C., White, B., Thein, H., Doab, A., Dore, G., Bates, A., et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care 20:1 (2008), 116–123.
19. Dore, G.J., Feld, J.J., Hepatitis C virus therapeutic development: In pursuit of perfectovir. Clinical Infectious Diseases 60:12 (2015), 1829–1836.
20. Drainoni, M.L., Litwin, A.H., Smith, B.D., Koppelman, E.A., McKee, M.D., Christiansen, C.L., et al. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. American Journal of Public Health 102:11 (2012), e115–121.
21. Easterbrook, P.J., Who to test and how to test for chronic hepatitis C infection—2016 WHO testing guidance for low- and middle-income countries. Journal of Hepatology 65:1 Suppl (2016), S46–S66.
22. Falade-Nwulia, O., Mehta, S.H., Lasola, J., Latkin, C., Niculescu, A., O'Connor, C., et al. Public health clinic-based hepatitis C testing and linkage to care in Baltimore. Journal of Viral Hepatitis 23:5 (2016), 366–374.
23. Ford, M.M., Johnson, N., Desai, P., Rude, E., Laraque, F., From care to cure: Demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients. Clinical Infectious Diseases 65:5 (2016), 685–691 (ciw806).
24. Foucher, J., Reiller, B., Jullien, V., Leal, F., di Cesare, E.S., Merrouche, W., et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: A prospective study. Journal of Viral Hepatitis 16:2 (2009), 121–131.
25. Gardner, E.M., McLees, M.P., Steiner, J.F., Del Rio, C., Burman, W.J., The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases 52:6 (2011), 793–800.
26. Grebely, J., Genoway, K.A., Raffa, J.D., Dhadwal, G., Rajan, T., Showler, G., et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence 93:1 (2008), 141–147.
27. Grebely, J., Knight, E., Genoway, K.A., Viljoen, M., Khara, M., Elliott, D., et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology & Hepatology 22:3 (2010), 270–277.
28. Grebely, J., Page, K., Sacks-Davis, R., Loeff, M.S., Rice, T.M., Bruneau, J., et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:1 (2014), 109–120.
29. Grebely, J., Lamoury, F.M.J., Hajarizadeh, B., Mowat, Y., Marshall, A.D., Bajis, S., et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: A cohort study. The Lancet Gastroenterology & Hepatology 2:7 (2017), 514–520, 10.1016/S2468-1253(17)30075-4.
30. Hagedorn, H., Dieperink, E., Dingmann, D., Durfee, J., Ho, S.B., Isenhart, C., et al. Integrating hepatitis prevention services into a substance use disorder clinic. Journal of Substance Abuse Treatment 32:4 (2007), 391–398.
31. Hajarizadeh, B., Grebely, J., Matthews, G., Martinello, M., Dore, G. (2016). Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments. Paper presented at the Hepatology.
32. Harris, K.A., Arnsten, J.H., Litwin, A.H., Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. Journal of Addiction Medicine 4:1 (2010), 20–26.
33. Hickman, M., McDonald, T., Judd, A., Nichols, T., Hope, V., Skidmore, S., et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial. Journal of Viral Hepatitis 15:4 (2008), 250–254.
34. Higgins, J., Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2013, The Cochrane Collaboration, 2011.
35. Ho, S.B., Brau, N., Cheung, R., Liu, L., Sanchez, C., Sklar, M., et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clinical Gastroenterology and Hepatology, 13(11), 2015 −2005–2014 e2003).
36. Islam, M.M., Topp, L., Conigrave, K.M., White, A., Reid, S.E., Grummett, S., et al. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment 43:4 (2012), 440–445.
37. Iversen, J., Grebely, J., Topp, L., Wand, H., Dore, G., Maher, L., Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011. Journal of Viral Hepatitis 21:3 (2014), 198–207.
38. Keats, J., Micallef, M., Grebely, J., Hazelwood, S., Everingham, H., Shrestha, N., et al. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy 26:10 (2015), 999–1006.
39. Lacey, C., Ellen, S., Devlin, H., Wright, E., Mijch, A., Hepatitis C in psychiatry inpatients: Testing rates, prevalence and risk behaviours. Australasian Psychiatry 15:4 (2007), 315–319.
40. Lambert, J.S., Murphy, C., Patel, A., Crowley, D., Stewart, S., Farrell, J., et al. Opportunistic fibroscan testing in a dublin general practice (GP) managing opiate substitution therapy: The hepcare study. Journal of Hepatology 1 (2016), S725–S726.
41. Lazarus, J.V., Sperle, I., Spina, A., Rockstroh, J.K., Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. Croatian Medical Journal 57:5 (2016), 442–456.
42. Liakina, V., Hamid, S., Tanaka, J., Olafsson, S., Sharara, A., Alavian, S., et al. Historical epidemiology of hepatitis C virus (HCV) in select countries–volume 3. Journal of Viral Hepatitis 22:S4 (2015), 4–20.
43. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Medicine, 6(7), 2009, e1000100.
44. Litwin, A.H., Smith, B.D., Drainoni, M.-L., McKee, D., Gifford, A.L., Koppelman, E., et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Digestive and Liver Disease 44:6 (2012), 497–503.
45. Lloyd, A.R., Clegg, J., Lange, J., Stevenson, A., Post, J.J., Lloyd, D., et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clinical Infectious Diseases 56:8 (2013), 1078–1084.
46. Malnick, S., Sheidvasser, V., Basevitz, A., Levit, S., A model for treating HCV hepatitis in patients receiving methadone maintenance therapy. Israel Journal of Psychiatry and Related Sciences 51:4 (2014), 303–306.
47. Marshall, A., Micallef, M., Erratt, A., Telenta, J., Treloar, C., Everingham, H., et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. International Journal of Drug Policy 26:10 (2015), 984–991.
48. Martin, N.K., Hickman, M., Hutchinson, S.J., Goldberg, D.J., Vickerman, P., Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 57:Suppl. 2 (2013), S39–S45.
49. Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58:5 (2013), 1598–1609.
50. Martinez, A.D., Dimova, R., Marks, K.M., Beeder, A.B., Zeremski, M., Kreek, M.J., et al. Integrated internist – addiction medicine – hepatology model for hepatitis C management for individuals on methadone maintenance. Journal of Viral Hepatitis 19:1 (2012), 47–54.
51. Masson, C.L., Delucchi, K.L., McKnight, C., Hettema, J., Khalili, M., Min, A., et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. American Journal of Public Health 103:10 (2013), e81–e88.
52. Merchant, R.C., Baird, J.R., Liu, T., Taylor, L.E., Montague, B.T., Nirenberg, T.D., Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population. Academic Emergency Medicine 21:7 (2014), 752–767.
53. Merchant, R.C., DeLong, A.K., Liu, T., Baird, J.R., Factors influencing uptake of rapid HIV and hepatitis C screening among drug misusing adult emergency department patients: Implications for future HIV/HCV screening interventions. Aids and Behavior 19:11 (2015), 2025–2035.
54. Meyer, J.P., Moghimi, Y., Marcus, R., Lim, J.K., Litwin, A.H., Altice, F.L., Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. International Journal of Drug Policy 26:10 (2015), 922–935.
55. Moessner, B.K., Jørgensen, T.R., Skamling, M., Vyberg, M., Junker, P., Pedersen, C., et al. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 106:5 (2011), 970–976.
56. Morano, J.P., Zelenev, A., Lombard, A., Marcus, R., Gibson, B.A., Altice, F.L., Strategies for hepatitis C testing and linkage to care for vulnerable populations: Point-of-care and standard HCV testing in a mobile medical clinic. Journal of Community Health 39:5 (2014), 922–934.
57. Moussalli, J., Delaquaize, H., Boubilley, D., Lhomme, J.P., Ponty, J.M., Sabot, D., Factors to improve the management of hepatitis C in drug users: An observational sudy in an addiction centre. Gastroenterology Research and Practice, 2010, 2010, 4.
58. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet 378:9791 (2011), 571–583.
59. Newman, A.I., Beckstead, S., Beking, D., Finch, S., Knorr, T., Lynch, C., et al. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Canadian Journal of Gastroenterology 27:4 (2013), 217–223.
60. O'Sullivan, M., Williams, H., Jones, A.M., Verma, S., Non-invasive detection, stratification and treatment of chronic hepatic C related liver disease amongst substance users in the community: A prospective study. Journal of Hepatology, 62, 2015, S595.
61. Pace, C.A., Tsui, J.I., Nader, C., Bergeron, L.P., LaBelle, C.T., Samet, J.H., Integrating care for hepatitis C virus infection with office-based therapy for opioid dependence. Journal of General Internal Medicine, 29, 2014, S488.
62. Radley, A., Melville, K., Tait, J., Stephens, B., Evans, J.M., Dillon, J.F., A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland. Frontline Gastroenterology 8:3 (2017), 221–228 (flgastro-2016-100776).
63. Remy, A.J., Bouchkira, H., Wenger, H., Montabone, S., News tools of screening viral hepatitis in real life: New french model of care. United European Gastroenterology Journal, 1, 2015 (A157).
64. Rosenberg, S.D., Goldberg, R.W., Dixon, L.B., Wolford, G.L., Slade, E.P., Himelhoch, S., et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatric Services 61:9 (2010), 885–891.
65. Roux, P., Castro, D.R., Ndiaye, K., Debrus, M., Protopopescu, C., Le Gall, J.M., et al. Increased uptake of HCV testing through a community-based educational intervention in difficult-to-reach people who inject drugs: Results from the ANRS-AERLI study. Public Library of Science, 11(6), 2016.
66. Sahajian, F., Bailly, F., Vanhems, P., Fantino, B., Vannier-Nitenberg, C., Fabry, J., et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. Journal of Public Health (Oxford) 33:2 (2011), 182–192.
67. Saraswat, V., Norris, S., Knegt, R.D., Sanchez Avila, J., Sonderup, M., Zuckerman, E., et al. Historical epidemiology of hepatitis C virus (HCV) in select countries–volume 2. Journal of Viral Hepatitis 22:s1 (2015), 6–25.
68. Seidenberg, A., Rosemann, T., Senn, O., Patients receiving opioid maintenance treatment in primary care: Successful chronic hepatitis C care in a real world setting. Bmc Infectious Diseases, 2013, 13, 10.1186/1471-2334-13-9.
69. Sena, A.C., Willis, S.J., Hilton, A., Anderson, A., Wohl, D.A., Hurt, C.B., et al. Efforts at the frontlines: Implementing a hepatitis C testing and linkage-to-care program at the local public health level. Public Health Reports 131 (2016), 57–64.
70. Skipper, C., Guy, J.M., Parkes, J., Roderick, P., Rosenberg, W.M., Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: Implications for the national strategy. Gut 52:10 (2003), 1500–1504.
71. Soulier, A., Poiteau, L., Rosa, I., Hezode, C., Roudot-Thoraval, F., Pawlotsky, J.M., et al. Dried blood spots: A tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. Journal of Infectious Diseases 213:7 (2016), 1087–1095.
72. Sterne, J.A., Hernán, M.A., Reeves, B.C., Savović, J., Berkman, N.D., Viswanathan, M., et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, 2016 (i4919).
73. Swan, D., Long, J., Carr, O., Flanagan, J., Irish, H., Keating, S., et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDs 24:12 (2010), 753–762.
74. Tait, J.M., McIntyre, P.G., McLeod, S., Nathwani, D., Dillon, J.F., The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. Journal of Viral Hepatitis 17:10 (2010), 698–704.
75. Tait, J.M., Stephens, B.P., McIntyre, P., Evans, M., Dillon, J.F., Dry blood spot testing for hepatitis C in people who injected drugs: Reaching the populations other tests cannot reach. Journal of Hepatology, 58, 2013, S204.
76. Treloar, C., Hull, P., Dore, G.J., Grebely, J., Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug and Alcohol Review 31:7 (2012), 918–924.
77. Trooskin, S.B., Poceta, J., Towey, C.M., Yolken, A., Rose, J.S., Luqman, N.L., et al. Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. Journal of General Internal Medicine 30:7 (2015), 950–957.
78. Wade, A.J., Macdonald, D.M., Doyle, J.S., Gordon, A., Roberts, S.K., Thompson, A.J., et al. The cascade of care for an Australian community-based hepatitis C treatment service. Public Library of Science, 10(11), 2015.
79. White, B., White, B., Day, C., White, B., Day, C., Thein, H.H., et al. Acceptability of hepatitis C virus testing methods among injecting drug users. Drug and Alcohol Review 27:6 (2008), 666–670.
80. Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K.J., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention. Public Library of Science, 9(7), 2014, e103345.
81. Woodrell, C., Weiss, J., Branch, A., Gardenier, D., Krauskopf, K., Kil, N., et al. Primary care-based hepatitis C treatment outcomes with first-generation direct-acting agents. Journal of Addiction Medicine 9:5 (2015), 405–410.
82. World Health Organization, WHO global hepatitis report 2017., 2017 Retrieved from: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
83. Yehia, B.R., Schranz, A.J., Umscheid, C.A., Lo Re, V. 3rd, The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. Public Library of Science, 9(7), 2014, e101554.
84. Zhou, K., Fitzpatrick, T., Walsh, N., Kim, J.Y., Chou, R., Lackey, M., et al. Interventions to optimise the care continuum for chronic viral hepatitis: A systematic review and meta-analyses. The Lancet Infectious Diseases 16:12 (2016), 1409–1422.